摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(3-羟基苯基)环丁烷羧酸 | 1307837-71-3

中文名称
1-(3-羟基苯基)环丁烷羧酸
中文别名
——
英文名称
1-(3-Hydroxyphenyl)cyclobutanecarboxylic acid
英文别名
1-(3-hydroxyphenyl)cyclobutane-1-carboxylic acid
1-(3-羟基苯基)环丁烷羧酸化学式
CAS
1307837-71-3
化学式
C11H12O3
mdl
——
分子量
192.214
InChiKey
XPLXXRORHQEJPG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    404.3±38.0 °C(Predicted)
  • 密度:
    1.332±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    57.5
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2918290000

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-(3-羟基苯基)环丁烷羧酸4-二甲氨基吡啶三溴化硼盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下, 以 二氯甲烷 为溶剂, 生成 N-(5'-chloro-2',4'-dihydroxyphenyl)-1-(3-hydroxyphenyl)cyclobutanecarboxyamide
    参考文献:
    名称:
    Identification of A Novel Small-Molecule Binding Site of the Fat Mass and Obesity Associated Protein (FTO)
    摘要:
    N-(5-Chloro-2,4-dihydroxyphenyl)-1-phenylcyclobutanecarboxamide (N-CDPCB, 1a) is found to be an inhibitor of the fat mass and obesity associated protein (FTO). The crystal structure of human FTO with la reveals a novel binding site for the FTO inhibitor and defines the molecular basis for recognition by FTO of the inhibitor. The identification of the new binding site offers new opportunities for further development of selective and potent inhibitors of FTO, which is expected to provide information concerning novel therapeutic targets for treatment of obesity or obesity-associated diseases.
    DOI:
    10.1021/acs.jmedchem.5b00702
  • 作为产物:
    描述:
    3-羟基苯乙腈 在 potassium hydroxide 作用下, 以 乙二醇二甲基亚砜 为溶剂, 生成 1-(3-羟基苯基)环丁烷羧酸
    参考文献:
    名称:
    Identification of A Novel Small-Molecule Binding Site of the Fat Mass and Obesity Associated Protein (FTO)
    摘要:
    N-(5-Chloro-2,4-dihydroxyphenyl)-1-phenylcyclobutanecarboxamide (N-CDPCB, 1a) is found to be an inhibitor of the fat mass and obesity associated protein (FTO). The crystal structure of human FTO with la reveals a novel binding site for the FTO inhibitor and defines the molecular basis for recognition by FTO of the inhibitor. The identification of the new binding site offers new opportunities for further development of selective and potent inhibitors of FTO, which is expected to provide information concerning novel therapeutic targets for treatment of obesity or obesity-associated diseases.
    DOI:
    10.1021/acs.jmedchem.5b00702
点击查看最新优质反应信息

文献信息

  • [EN] CARBOXYLIC ACID-CONTAINING COMPOUNDS, DERIVATIVES THEREOF, AND RELATED METHODS OF USE<br/>[FR] COMPOSÉS CONTENANT DE L'ACIDE CARBOXYLIQUE, LEURS DÉRIVÉS ET PROCÉDÉS D'UTILISATION ASSOCIÉS
    申请人:BIOGEN IDEC INC
    公开号:WO2010138901A1
    公开(公告)日:2010-12-02
    Compounds that modulate gamma secretase (e.g., alter the cleavage pattern of gamma secretase) are described herein. Also disclosed are pharmaceutical compositions, methods of modulating the activity of gamma secretase, and methods of treating Alzheimer's Disease using the compounds described herein.
    本文件描述了调节γ-分泌酶(例如,改变γ-分泌酶的切割模式)的化合物。还公开了包含这些化合物的药物组合物、调节γ-分泌酶活性的方法,以及使用本文件描述的化合物治疗阿尔茨海默病的方法。
  • Identification of A Novel Small-Molecule Binding Site of the Fat Mass and Obesity Associated Protein (FTO)
    作者:Wu He、Bin Zhou、Weijia Liu、Meizi Zhang、Zhenhua Shen、Zhifu Han、Qingwei Jiang、Qinghua Yang、Chuanjun Song、Ruiyong Wang、Tianhui Niu、Shengna Han、Lirong Zhang、Jie Wu、Feima Guo、Renbin Zhao、Wenquan Yu、Jijie Chai、Junbiao Chang
    DOI:10.1021/acs.jmedchem.5b00702
    日期:2015.9.24
    N-(5-Chloro-2,4-dihydroxyphenyl)-1-phenylcyclobutanecarboxamide (N-CDPCB, 1a) is found to be an inhibitor of the fat mass and obesity associated protein (FTO). The crystal structure of human FTO with la reveals a novel binding site for the FTO inhibitor and defines the molecular basis for recognition by FTO of the inhibitor. The identification of the new binding site offers new opportunities for further development of selective and potent inhibitors of FTO, which is expected to provide information concerning novel therapeutic targets for treatment of obesity or obesity-associated diseases.
查看更多